Clinical Performance of the Nipro ELISIO HX Medium Cut-Off Dialyzer

Clinical Performance of the Nipro ELISIO HX Medium Cut-Off Dialyzer - Performance of the Nipro ELISIO HX Dialyzer

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

DRKS

Registry ID

DRKS00026806

Enrollment

Registered

2021-10-08

Start date

2021-10-18

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N18.5

Interventions

Group 1: Hemodialysis with the Nipro ELISIO 17HX dialyzer Group 2: Hemodialysis with the Baxter Theranova 400 dialyzer

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: • Age = 18 years • End-stage kidney disease • Chronic hemodialysis treatment for more than three months • Hematocrit = 30 % • Stable anticoagulation and erythropoietin regimen • No vascular access-related problems (A/V-fistula or bi-flow catheter) • No ongoing infection • Signed informed consent form

Exclusion criteria

Exclusion criteria: • Inclusion criteria not met • Known HIV infection. • Pregnancy • Unstable clinical condition (e.g., cardiac or vascular instability) • Life expectancy less than 12 months • Known coagulation problems • Participation in another study interfering with the planned trial

Design outcomes

Primary

Measure	Time frame
Removal of the solutes urea, creatinine, phosphate, beta-2-microglobulin, myoglobin, IL6, TNF-alpha, kappa and lambda light chains during hemodialysis	—

Secondary

Measure	Time frame
Albumin loss into dialysate during hemodialysis	—

Countries

Germany

Contacts

Public ContactDetlef Krieter

Dialysezentrum Elsenfeld

krieter_d@ukw.de+49-6022-2655666

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026